The tumor suppressor p53 has been found to be the most commonly mutated gene in human cancers; however, the frequency of p53 mutations varies from 10 to 70% across different cancer types. This variability can partly be explained by inactivating mechanisms aside from direct genomic polymorphisms. The p53 gene encodes 12 isoforms, some of which can modulate fulllength p53 activity in cancer. In this study, we characterized p53 isoform expression patterns in glioblastoma, gliosis, non-tumor brain and neural progenitor cells by SDS-PAGE, immunoblot, mass spectrometry and reverse transcription-PCR. We found that the most consistently expressed isoform in glioblastoma, D40p53, was uniquely expressed in regenerative processes, such as those involving neural progenitor cells and gliosis compared with tumor samples. Isoform profiling of glioblastoma tissues revealed the presence of both D40p53 and full-length p53, neither of which were detected in non-tumor cerebral cortex. Upon xenograft propagation of tumors, p53 levels increased. The variability of overall p53 expression and relative levels of isoforms suggest fluctuations in subpopulations of cells with greater or lesser capacity for proliferation, which can change as the tumor evolves under different growth conditions.
INTRODUCTION
The tumor suppressor p53 has been found to be the most commonly mutated gene in human cancers. [1] [2] [3] [4] [5] However, the frequency of p53 mutations in each individual cancer type varies from 10 to 70%. [6] [7] [8] [9] These data suggest that mechanisms aside from direct p53 gene mutation may be important in cancer development. In glioblastoma, p53 mutations have not been identified as a necessary step in tumor progression. 6, 10 The p53 gene can potentially encode a family of 12 isoforms, some of which have been found in both cancer [11] [12] [13] [14] [15] and normal development. 16 A specific function for each isoform has yet to be defined, although some p53 isoforms have been shown to alter the function of the parent p53. [11] [12] [13] [14] 17, 18 D40p53 (also known as DNp53, p44, or p53/47) was first identified in the mouse as a naturally occurring isoform present in Friend virus-induced tumors lacking full-length p53. 19, 20 Subsequent studies have focused on investigating endogenous p53 isoform expression in human cancers. 11, 13, 14, 19 The complexity of determining the frequency and mode of non-genomic p53 inactivation in cancers can be partly attributed to the function of the numerous p53 isoforms. 1, 20 p53 mutations and protein levels have been extensively characterized in tumors primarily by sequencing and immunohistochemistry; 1,2 however, these methods alone are insufficient in distinguishing specific isoforms owing to the complex regulation of p53 at the transcriptional, translational and intermolecular level. 20, 21 This is particularly true for D40p53, which can only be reliably detected using protein-based methods. Although most p53 isoforms arise by alternative splicing or alternate promoter usage, 20 D40p53 is generated primarily by a mechanism involving alternative translation initiation of an mRNA shared with fulllength p53. Utilization of a start site in exon 2 initiates at amino acid 1 and generates p53, while utilization of a start site in exon 4 initiates at amino acid 41 and produces D40p53. [22] [23] [24] [25] D40p53 can also be expressed by alternative splicing of intron 2 in some cell types, 12, 17, 18, 26 but such a mechanism appears to contribute only a minor portion of total D40p53 levels. 17, 27 Given that p53 executes its primary function as a transcription factor, which is a tetramer of p53 monomers that require both N-and C-terminal domains for full activity, isoforms that differ in their domain structure could significantly alter function even in the absence of p53 sequence changes. We characterized p53 isoform expression patterns in glioblastoma, gliosis (GLS), nontumor brain and neural progenitor cells using a combination of methods including (but not limited to) SDS-PAGE, immunoblot and mass spectrometry. Such an approach allowed us to examine differences in endogenous p53 isoform protein patterns across tumor and non-tumor brain specimens.
RESULTS

D40p53 is a major isoform in glioblastoma multiforme (GBM)
We initially examined 17 glioblastoma xenograft tissues (GBM XT) for p53 isoform expression by western blot analysis using CM1, a polyclonal antibody against p53 (Figure 1a ). The tumors were derived from 12 male, 3 female and 2 unidentified patients ranging in age from 41 to 82 years (mean age 62), and were located either in the parietal, frontal or temporal cortex, or in the cerebellum (Table 1) . We detected a total of three immunoreactive bands between the 37-and 50-kDa markers in this initial panel of tumors. In addition to p53 at approximately 50 kDa, these bands could represent any one of four isoforms that migrate with apparent molecular weights within this range: D40p53 (48 kDa); p53b (46 kDa); p53g (46 kDa), and Dp53 (44 kDa). Although very similar in MW, these isoforms lack specific regions of the full-length protein, as diagrammed in Figure 1b , and are easily distinguished from one another using epitope-specific antibodies. Epitopes recognized by the various antibodies used in this study are indicated at the top of the diagram in Figure 1b . D40p53 is Figure 1 . D40p53 is a major isoform in glioblastoma. (a) Western blot analysis of p53 isoforms in GBM XT samples using CM1, DO1 and pAb421. Approximate molecular weights are given to the right, indicating p53 (50 kDa) and a smaller isoform (45 kDa) that is detected by pAb421 and not DO1. The DO1/pAb421 overlay shows that the 45-kDa band is distinct from another band detected by DO1 that ran closer to the 37-kDa marker (most prominent in GBM XT 28 and 36). Single asterisk (*) indicates samples with a p53 DNA-binding domain mutation (see Table 1 ). (b) Diagrammatic representation of the p53 isoforms identified in this study. p53 domains are indicated by boxes: transcription factor domain (TFD-1, -2), proline domain (PrD), DNA binding domain (DBD), nuclear localization signal (NLS), tetramerization domain (Tet), regulatory (basic) domain (Reg). Antibodies used to recognize specific isoforms are indicated at the top. DO1, DO7 and BP53-12 recognize N-terminal epitopes of p53 and pAb421 recognizes the C-terminus (will not detect b or g isoforms). The pAb421 epitope overlaps with several post-translational modifications. CM1 is a rabbit polyclonal antibody raised against full-length p53. Genomic sequencing identified a GT to CT transversion in the donor splice site for intron 5. cDNA sequencing indicated that this resulted in utilization of a cryptic splice donor site 43 bp upstream of the normal donor site, which caused deletion of 14 amino acids at the 3 0 end of exon 5. Exon 6 sequences were present in their entirety. The resultant D40p53 protein is missing a short piece of the DNA binding domain. , and can be differentiated from the other three using monoclonal antibodies DO1, DO7, DO13 and BP53-12, which map in this region. p53b and p53g have alternate C-terminal amino acids and lose the epitope detected by pAb421. Dp53 is missing amino acids in the central region of the protein, but retains both the N-terminal epitope missing in D40p53 and the C-terminal epitope missing in p53b and p53g. To identify the isoforms prevalent in the tumors, we used the N-terminal monoclonal antibody DO1 and the C-terminal monoclonal antibody pAb421 on the same panel of GBM XT (Figure 1a ). Using DO1, we found a band at approximately 50 kDa in 16 of 17 tumors (Figure 1a , DO1) and a band slightly above 37 kDa in less than half of the samples (most visible in GBM XT 28 and 36, Figure 1a , DO1). Using pAb421 (Figure 1a, pAb421) , we saw the appearance of a band not found in DO1 at approximately 45 kDa in 16 of 17 samples. This 45 kDa band detected by pAb421 did not overlap with the band migrating slightly above 37 kDa that was detected by DO1 ( Figure 1a , DO1/pAb421 overlay). We noted a difference in p53 detection by pAb421 compared with CM1 and attributed this difference to the sensitivity of pAb421 to post-translational modifications. Based on the known p53 isoforms that migrate at approximately 45 kDa, the isoform that would be detected by pAb421 but not DO1 is D40p53 (Figure 1b ). We tentatively identified this 45-kDa band as D40p53.
To verify the identity of p53 isoforms in GBM, we first used reverse transcription-PCR and primers that would amplify p53 and several different isoforms (Supplementary Figure S1) . We used standard reverse transcription-PCR conditions to amplify the unique intron 2 sequence found in D40p53 generated by alternative splicing, 12 and successfully amplified the predicted 360 bp amplicon (Supplementary Figure S2A) . However, sequencing results did not match the unique D40p53 intron 2 sequence. This suggested that alternative splicing was not the major mechanism involved in D40p53 production. Next, we used both single and nested PCR protocols designed to amplify p53b and p53g. 28 Using a single PCR reaction with p53b primers, we were able to detect products at the predicted size for p53b in GBM XT 10, 12, 16 and 22 at low levels. We did not find amplicons corresponding to p53g at the predicted 1 kb size (Supplementary Figure S2B) . Using nested PCR (see Supplementary Figure 1A legend for details), however, we did not detect amplicons corresponding to either p53b or p53g transcripts at the predicted 1 kb size, and we verified these results by sequencing ( Supplementary Figures S2C-E) . The low transcript levels of p53b seen with single PCR analysis corresponded to faint bands migrating above the D40p53 band on western blots that were detected by DO1, but not pAb421 (Figure 1a , best visualized in GBM XT16).
To continue with our analysis, we immunoprecipitated p53 proteins from GBM XT 43 (which expressed proteins at both 50 and 45 kDa, as shown in Figure 1a ) using DO1 or pAb421 monoclonal antibodies, the latter of which would not pull down b/g isoforms. The immunoprecipitated lysates were run on SDS-PAGE and silver stained ( Figure 2a ) and major bands were submitted for mass spectrometric analysis. We identified the band co-migrating with the 50-kDa marker (Band 2) as full-length p53 based on the recovered peptide sequences, which are indicated in red in Figure 2a . We identified the faster migrating band (Band 3) precipitated by the C-terminal pAb421 antibody as D40p53 based on apparent MW and the peptides recovered in the band, which span both the region deleted in Dp53 (vcacpgr and alpnntssspqpk) and the C-terminal domain missing in p53b and p53g (elnealelk). No p53 peptides were recovered from bands 1 or 4.
To compensate for the failure of mass spectrometry to detect any N-terminal peptides in bands 2 and 3, which would have allowed unambiguous identification of p53 or D40p53, we utilized a panel of monoclonal antibodies against epitopes in the N-terminal domain of p53 with isogenic cell lines that express either p53 and D40p53, or only D40p53. We compared immunoreactive bands in lysates from HCT116 colorectal cancer cells, which have a wildtype p53 (HCT116 þ / þ ), and from the HCT116 p53 À / À isogenic subline (Figure 2b ). The HCT116 À / À subline was derived by targeting a neomycin-resistance gene into the first codon of the p53 gene within exon 2. 29 The recombinant allele can no longer make full-length p53, p53b or p53g, which initiate in exon 2. However, it can and does produce D40p53 from the intact start codon in exon 4 utilized by endogenous D40p53. Thus, HCT116 À / À cells can be used as a control, in which the D40p53 isoform is expressed in the absence of full-length p53. As shown in Figure 2b , the polyclonal antibody CM1 detects a pair of bands in extracts of HCT116 þ / þ cells, but only the lower of these two bands in HCT116 À / À cells. N-terminal antibodies (DO1, DO7 and BP53-12) react with the upper band, which migrates at approximately 50 kDa, and a lower band migrating at approximately 44 kDa, but not the band migrating at approximately 48 kDa (Figure 2b ). Based on the known genotype of HCT116 þ / þ and À / À cells, the 50-and 48-kDa bands represent p53 and D40p53, respectively. Comparing these positively identified bands with bands detected in extracts from GBMs, we can unambiguously identify the single isoform present in GBM XT 22 as p53 ( Figure 2b , CM1, arrow) and the single isoform present in GBM XT 12 as D40p53 (Figure 2b , CM1, arrowhead). Thus, using the combination of mass spectrometry data and alignment with HCT cell lines expressing either p53 and D40p53 or D40p53 alone (Figures 2a and b) , we have been able to assign p53 and D40p53 to specific bands detected by antibody CM1 in GBM. We find that D40p53 is highly and consistently expressed in GBM. Full-length p53, as detected by the N-terminalspecific monoclonal antibody DO1 (Figure 1b) , is increased relative to D40p53 in some of the samples derived from tumors with an identified DNA binding domain mutation (GBM XT 6, 12, 22, 28, 36 and 43), as detailed in Table 1 . We detected additional higher molecular weight bands with CM1 in the GBM XT panel, which are marked with one, two or three asterisks on the full-sized western blots presented in Supplementary Figure S3 . The bands marked with one or two asterisks were also found in cells lacking p53 (Supplementary Figure S4A) , indicating that they do not represent any p53 isoform. The band marked with three asterisks was only present in cells with p53, but it was not recognized by antibodies against SUMO, Hsp70, p63 or p73 (Supplementary Figure S4B) , and its identity remains unknown. We also detected one prominent lower molecular weight band with CM1 in the GBM XT panel. This band, which migrated just above the 37-kDa marker, was detected in non-tumorous samples, gliosis (GLS 8) and cerebral cortex (CTX 9); however, it was also detected in p53-null cells (p53 À / À NSC, H1299, LNZ308) (Supplementary Figure  S5) , indicating that it too does not represent a form of p53.
Next, we used unambiguously identified isoforms in GBM XT 22 and GBM XT 12 ( Figure 2b ) as reference standards to aid in the assignment of co-migrating bands in samples of glioblastoma patient tissue (GBM PT), CTX, and GLS (Figures 2c-e) . First, we compared p53 isoform expression in GBM xenografts to that in primary tumors from patients diagnosed with Grade IV astrocytoma (GBM) according to the WHO Classification of Central Nervous System Tumors. 30 Tumors surgically removed from frontal, temporal, parietal or parieto-occipital brain regions were obtained from 7 male and 3 female patients aged 23-78 years (average 56 years) ( Table 2) . Compared with p53 peptides detected by CM1 in xenograft samples (Figure 1a) , smaller molecular weight p53 isoforms (o50 kDa) were detected at lower levels in primary tumor samples (Figure 2c ). There was a band corresponding to D40p53 in over half of the samples, most visibly in sample 5. Full-length p53 was detected at approximately 50 kDa, most prominently seen in samples 8 and 10. We could not detect p53 isoforms below the 37-kDa marker. In summary, of the p53 isoform profiling R Takahashi et al Figure 2 . Identification of p53 and D40p53 by mass spectrometry and isoform expression in patient glioblastoma, cortex and GLS. (a) Mass spectrometric identification of p53 and D40p53. p53 protein was immunoprecipitated from GBM XT 43 using either DO1 or pAb421.
Immunoprecipitates were subjected to SDS-PAGE and the gel was silver stained. Bands 1, 2 and 3 were submitted for mass spectrometric analysis. Peptide sequences in bands 2 and 3 that matched human p53 are indicated in red. No human p53 peptide sequences were recovered from bands 1 or 4. Of the recovered peptide sequences, vcacpgr, alpnntssspqpk and elnealelk are found in D40p53 but missing in Dp53 and p53b/y, respectively. Based on the known isoforms that migrate at B45 kDa (p53b/g, D40p53, and Dp53), the mass spectrometry data indicate that the 45-kDa band is D40p53. (b) p53 isoform detection in representative GBM XT, primary tissue, GLS and cortex. Extracts of HCT116 cells with intact p53 (HCT þ / þ ) and HCT116 cells with an insertion of Neo R into exon 2 (HCT À / À ) are used as a reference for p53 (arrow) and D40p53 (arrowhead), respectively. Isoforms were detected on western blots using a panel of antibodies: a polyclonal antibody, CM1, or N-terminal monoclonal antibodies (D07, D01 and BP53-12). GBM XT 12 expresses only the 45-kDa band (arrowhead) and GBM XT 22 expresses the upper 50-kDa band (arrowhead). The 45-kDa band in GLS 3 co-migrates with the D40p53 band in HCT cells (see arrowheads). (c) Western blot analysis of 10 GBM PT frozen samples using CM1. D40p53 and p53 were detected at lower levels than in GBM XT samples with the exception of GBM PT 10 where p53 level was comparable to GBM XT with DNA binding domain mutations (Figure 1a) . (d) Nine CTX and (e) 10 GLS tissues were analyzed for p53 isoform expression using CM1. We detected a 45-kDa band in GLS samples that co-migrated with the D40p53 band in HCT cells (b, arrowheads). GLS samples showed an isoform that migrated with an apparent MW of B55 kDa indicated by *** (see Supplementary Figure S3 ). Arrow next to CTX samples (d) indicates a band that was found in p53-null cells (Supplementary Figures S3  and S5 ). This band migrated below the D40p53 band when aligned with other samples including HCT cells, GBM XT 12 and GLS 3 (b). Western blot images were cropped for clarity and focus on relevant bands. Abbreviations: F, female; GBM, glioblastoma multiforme; GBM PT, glioblastoma patient tissues; M, male.
p53 isoform profiling R Takahashi et al p53 species detected by CM1, one of the most consistently expressed isoform in both GBM xenograft and patient material is D40p53. Full-length p53 is found less frequently, but can be detected at high levels in some tumors. Overall, p53 isoforms were detected at lower levels in patient-derived compared with xenograft-derived GBM.
Full-length p53 is associated with the tumor component of GBM PT To resolve the discrepancy in the levels of p53 isoforms detected in patient-derived ( Figure 2c ) and xenograft-derived (Figure 1a ) GBM, we compared p53 expression in primary tumors and serial passages of the same tumor engrafted into nude mice. Protein lysates were extracted from tumors at passage 1, 2, and 4 or 5 and compared with primary tumors by SDS-PAGE and western blot analysis using DO1 and CM1 (Figure 3 ). GBM 43 served as a control for p53 (arrow) and D40p53 (arrowhead). We found that D40p53 was expressed in four out of five primary GBMs and in all xenograft samples (48 kDa band detected by CM1 and not DO1). We could not detect p53 in any of the primary GBM samples; however, p53 was apparent in all passages of four out of five xenografts. Only GBM 121 did not express p53 in primary or xenograft conditions and was similar to GBM 12 ( Figure 1a ) in that only D40p53 could be detected. We noted that GBM 132 had increased levels of p53, which mimicked the levels seen in GBM xenografts with p53 DNA-binding domain mutations ( Figure 1 single asterisk and Table 1 ). To determine if p53 expression was a transient or long-term effect, we also examined xenografts from passages 30, 35 and 46, and found that p53 continued to be expressed at later passages (Supplementary Figure S6) . We confirmed that the increase in p53 upon serial passage was not due to contamination by surrounding host mouse tissue by using DO1, which detects an epitope in human p53 not present in mouse p53 (Figure 1b) . The p53 band did not disappear with DO1 ( Figure 3 , DO1 panel), indicating that the 50-kDa band detected by CM1 was in fact human p53. In summary, removal and growth of patient tumor sample in the environment of the nude mouse revealed full-length p53. This change in p53 expression occurred within the first passage in nude mice concurrent with the expansion of the tumor component of the resected material and was retained even in late passage serial xenografts.
Injury induces D40p53 in brain
To determine whether these patterns of p53 isoform expression were unique to tumors, we examined p53 isoform expression in 9 CTX samples from autopsy and 10 temporal lobe seizure resections classified as GLS (reactive astrocytosis) (Figures 2d  and e) . CTX specimens were collected from patients (5 female, 4 male) whose cause of death was unrelated to brain pathology. In contrast to glioblastoma specimens, GLS and CTX tissues exhibited a uniform p53 expression pattern across individual samples. Normal cortex was devoid of p53 expression (Figure 2d ). Gliotic samples, on the other hand, consistently expressed D40p53 (Figure 2e ). There was a complete and striking absence of full-length p53 in both GLS and normal cortex compared with xenograft-and patient-derived GBM (Figures 1a and 2c ). Consistent D40p53 expression in the absence of p53, therefore, is the distinguishing feature of tumorous vs non-tumorous brain.
D40p53 is a constituent of subventricular zone (SVZ) progenitor cells GBMs have been proposed to arise from the common glial/ neuronal precursor cells (NSCs) present in neurogenic regions of the adult brain. [31] [32] [33] [34] This theory is supported by behavioral and molecular characteristics shared by both cancer and progenitor cells, such as multipotency, proliferative capacity, signaling pathways and protein expression. [35] [36] [37] [38] To determine if the expression of p53 isoforms in glioblastoma might reflect that found in normal adult human neural progenitor cells, we cultured cells derived from the SVZ of elderly human subjects obtained by rapid autopsy protocol. 39 Cells were grown either in the presence of serum or of epidermal and fibroblast growth factors (EGF and FGF, respectively). When cells were propagated with EGF and FGF, 490% of the population of cells generated neurospheres (NS), which did not adhere to the surface of the culture plate (Figure 4a , top panel). On the other hand, when we replaced the growth factors with serum, cells grew as an adherent monolayer (ADH) with occasional, phase-bright foci that also adhered to the surface of the culture plate (Figure 4a, bottom panel) . Within this adherent culture, we visualized a heterogeneous population of cells, including those that resembled astrocytes (large cytoplasm with ruffled border) and others that resembled neurons, which had processes that were greater than four times the diameter of the cell body (Figure 4, arrowheads) . Similar cells were observed in the NS cultures, but were infrequent and comprised only a small percentage of the total population. Our characterization of the adult human SVZ cells was consistent with the results of a previous study of similar cultures from human rapid autopsies. 39 Both adherent and non-adherent cultures of adult human SVZ cells expressed D40p53, but not full-length p53, in contrast to GBM, which expressed both and normal cortex that expressed neither (Figure 4b ). There was also more D40p53 in NS cultures and tumor cells compared with levels seen in ADH cultures, suggesting that actively proliferating cells may express more of Figure 3 . Full-length p53 is associated with the tumor component of GBM PT. Western blot analysis of GBM PT (passage zero) and corresponding GBM XT (passage 1, 2, 4 or 5) using CM1 (top panel) and DO1 (middle panel). GBM XT 43 (passage 26) was used as a control to align p53 (arrow) and D40p53 (arrowhead) at B50 and 48 kDa, respectively. The 48-kDa band was detected by CM1 (not DO1) and corresponds to the 48-kDa band initially detected by pAb421 (Figure 1a) . DO1 does not recognize mouse p53 species. A DO1/CM1 overlay is included for clarity and western blot images were cropped to focus on relevant bands. p53 isoform profiling R Takahashi et al this isoform. This is consistent with our previous observation that D40p53 is an embryonic isoform of p53 that is associated with proliferating populations of stem cells. 16 As the pool of NSCs is known to decrease with age, 40 we used the model system of adult neurogenesis in the mouse to determine whether the level of D40p53 also decreased in aging neural progenitor cell populations. We harvested neural progenitor cells from the SVZ of embryonic day 14 (E14), 2.5-month-old (2.5 mo), and 14-month-old (14mo) mouse brain, as previously described, 40 and compared the expression of p53 isoforms by western blot. As shown in Figure 4c , we observed a decreasing trend in D40p53 expression with SVZ cells derived from older mice. Analysis of variation (ANOVA) did not show a statistically significant difference among the groups; however, we have consistently observed a decline in D40p53 levels within the aging brain. The low level of D40p53 in multipotent mouse neural progenitors, specifically derived from older mice, closely resembled the level of D40p53 in SVZ cells derived from elderly humans (Figure 4b ). Pluripotent embryonic stem cells (ESCs), on the other hand, with their prominent expression of both D40p53 and full-length p53 (Figure 4c ), more closely resembled the p53 isoform expression pattern seen in human GBM. We confirmed the identity of D40p53 using CM1 and an N-terminal monoclonal antibody against murine p53 (1C12), which reacted with p53 but not D40p53 in mouse cells (Supplementary Figure S7) .
To determine whether the loss of D40p53 expression with age might reflect the decreasing ability of aging NSCs to remain multipotent, we compared the expression of D40p53 in populations of murine SVZ cell cultures forced to undergo the transition from non-adherent (NS) to adherent monolayer (ADH) growth and then induced to differentiate into neuronal and glial progeny. Sequential removal of EGF and FGF resulted in a loss of D40p53 expression between days 0 and 4 in vitro, followed by an increase in D40p53 expression over the course of the next 3 days in the presence of serum (Figures 5a  and b) .
At day 7 in vitro, cells were harvested and analyzed for the presence of differentiated progeny by immunocytochemistry using antibodies against nestin, glial fibrillary acidic protein (GFAP), O 4 , and b-tubulin. Representative images of murine and cultured human adult SVZ cells analyzed by immunocytochemistry with these antibodies are presented in Figure 5c . NSCs are nestin and GFAP double positive cells (nestin þ GFAP þ ) [41] [42] [43] [44] [45] [46] [47] that have the potential to differentiate into an astrocyte (GFAP single positive), oligodendrocyte (O 4 single positive) or a neuron (b-tubulin single positive). [48] [49] [50] [51] Based on the staining pattern of these differentiation markers, we concluded that the differentiation state of mouse embryonic NSCs at day 7 after growth factor withdrawal was comparable with adult human SVZ progenitor cells that had been grown in serum post-mortem. More specifically, the majority of mouse and adult human cells were either NSCs or astrocytes (Table 3) . Neurons were not detected in either cell population, and oligodendrocytes were only found in the human NSC population. A detailed description of each immunophenotype is given in the Supplementary Text accompanying Supplementary Figure S8 . We concluded that the differentiation state (based on these markers) and levels of D40p53 seen in mouse SVZ cells resembled those seen in adult human-derived cells.
Again, the most remarkable difference between SVZ progenitor cells and glioblastoma cells was the complete absence of fulllength p53. This pattern correlated with the appearance of differentiated cells identified by immunocytochemistry with antibodies specific for immature and mature neuronal and nonneuronal derivatives of SVZ cultures. Figure S5 ). (c) SVZ-derived neural progenitor cells from embryonic day 14 (E14) or adult brain at 2.5 months (2.5mo) and 14 months (14mo) of age analyzed by western blot using pAb421. p53 isoform expression was compared with total brain tissue (expresses neither p53 or D40p53) and mouse ESCs, which expresses both. Bar graph below shows relative D40p53 levels from the western blot above, and triplicate experiments are represented in (d). Analysis of variance (ANOVA) did not reveal statistically significant differences between groups despite the decreasing trend in D40p53 levels observed in SVZ cultures from older mice (see main text). Western blot images were cropped to enhance clarity and focus on relevant p53 bands. The distinguishing feature of GBM is the presence of both D40p53 and full-length p53, a profile also seen in pluripotent (embryonic) stem cells. Changes in the relative levels of these two p53 isoforms in ESCs can switch cells from the highly proliferative, pluripotent state of the undifferentiated ESC to that of a differentiated somatic cell with limited proliferative capacity and potency. 16 The observation that the isoform profile of GBM xenografts resembles that of highly proliferative, undifferentiated stem cells may be a clue to the state of GBM cells relative to other cancer cells that may not express D40p53. In contrast, both adult SVZ progenitor cells and gliotic brain tissue undergo proliferation at much lower rates, and in response to injury, share a p53 isoform profile characterized by the expression of D40p53 in the absence of full-length p53. Furthermore, differentiated SVZ progenitor cells and tissue from normal brain express low to undetectable levels of D40p53 and no p53. In conclusion, the neural progenitor marker, D40p53, is increased in the astrocytic reaction to injury and in GBM, both of which have the capacity to proliferate, 52, 53 but not in CTX, which is primarily composed of terminally differentiated cells, or in the differentiated progeny of SVZ progenitors.
A question that remains to be answered is how p53 isoforms, such as D40p53, function in the presence of mutant p53. A mutation in p53 would affect all isoforms containing the mutant domain. In the case of a heterozygous mutation, however, mutant and normal isoforms could interact, leading to situations in which a normal version of D40p53 could interact with a mutant form of p53 and rescue function. For example, a mutant p53 that is defective in DNA binding could pair with a wildtype D40p53 competent for DNA binding, resulting in a heterotetrameric transcription factor. In the same heterozygous context, however, a mutant D40p53 isoform could have a dominant-negative effect on the wildtype p53 protein, similar to the dominant-negative effect of mutant p53 proteins on wildtype protein function. [54] [55] [56] This could account for some of the variability seen in response to cancer treatment, as well as the mixed success of targeted p53 therapies.
Even in the absence of DNA sequence alterations, however, heterotetramers comprising p53 and D40p53 monomers could exhibit decreased or increased p53 tumor-suppressor activity depending on how specific p53 targets are affected by the loss of one or more transactivation domains. Furthermore, because the Mdm2 binding domain is localized to the transactivation domain, heterotetramers with D40p53 could also reduce Mdm2 binding and increase the effective half-life of the transcription factor. 23 This can explain the increased levels of p53 targets, such as p21, in SVZ progenitor cells from mice with an increased dose of D40p53. 40 It is also possible that increased D40p53 in tumors could meet a compensatory increase in Mdm2 levels (though we did not observe increased Mdm2 expression in GBM xenografts, Supplementary Figure S9) .
Deciphering the ultimate effects of increased p53 isoform expression in tumor development remains open for further study and is particularly warranted owing to the increased levels of p53 seen in malignant cancers and pre-cancerous lesions even in the absence of mutations in the p53 gene. One of the goals is to understand how the specific expression patterns of p53 isoforms in cancer compare with their expression in non-cancerous tissue that can undergo only limited proliferation. Insight into such endogenous isoform levels could provide novel approaches in controlling tumor growth.
MATERIALS AND METHODS
Mass spectrometry
Protein lysates were prepared from GBM XT 43 tumor tissue and immunoprecipitated using p53 antibodies DO1 (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) and pAb421 (Calbiochem/EMD Chemicals, Gibbstown, NJ, USA), as previously described. 57 Immunoprecipitates were denatured and electrophoresed on a 10% Tris-HCl gel and silver stained according to manufacturer's protocol (BioRad, Hercules, CA, USA). Bands were excised from the gel and submitted for mass spectrometry analysis.
Western blot analysis
Protein lysates were prepared from frozen tissue samples and analyzed for p53 isoform expression by western blot. 16 Protein concentration was determined using a BCA assay according to manufacturer's protocol (BioRad). Nitrocellulose membranes were incubated overnight at 4 1C with gentle shaking in primary antibodies at a 1:1000 dilution in either 1 Â TBST or blocking buffer (5% milk or BSA) as indicated. Antibody sources include the following: DO1 in 1 Â TBST (Santa Cruz Technologies Inc.), pAb421 in 1 Â TBST (Calbiochem/EMD Chemicals), phospho-p53 (ser15P) in 5% BSA (Cell Signaling, Danvers, MA, USA) and CM1 in 5% milk (Vector Labs, Burlingame, CA, USA), SUMO-1 (Cell Signaling), Hsp70 (Cell Signaling), p63 (Cell Signaling), p73 (5B1288) (Abcam, Cambridge, MA, USA), GAPDH (Ambion, Foster City, CA, USA) and actin (MPBio Biomedicals, Solon, OH, USA).
Patient, xenograft and mouse samples
Frozen patient tissues were obtained from the Mayo Clinic Brain SPORE and Biospecimens Committee according to Institutional Review Board standards. Primary human GBM xenografts were derived from human tissue as previously described. 58 All tissues were frozen and maintained at À 80 1C until use. p53-null NSCs were derived from the SVZ of mice (Taconic Farms Inc., Hudson, NY, USA) and p53-competent ESCs were harvested from CD1 mice (Harlan Laboratories, Indianapolis, IN, USA) as previously described. 16 H1299 and LNZ308 are human cancer cell lines (lung carcinoma and glioblastoma, respectively) that are p53-null. 10, 59, 60 Mouse NSCs were maintained as spheres in the presence of EGF (20 ng/ml) and FGF (20 ng/ml) (Invitrogen, Carlsbad, CA, USA) in ultra-low attachment tissue culture plates (Corning, Lowell, MA, USA). 40 NSCs were plated on a poly-L-ornithine treated surface in the absence of EGF on day 0, and the remaining FGF was replaced by 2% fetal bovine serum in DMEM (Gibco, Carlsbad, CA, USA) on day 3 before harvesting samples the following day. 61 Adult human NSCs were cultured either as NS in the absence of serum with growth factors, EGF (20 ng/ml) and FGF (10 ng/ml) (Peprotech, Rocky Hill, CT, USA) or as an adherent monolayer (ADH) with serum as previously described. 39 Immunofluorescence Embryonic mouse and adult human NSCs were plated on poly-L-ornithinetreated and poly-L-lysine-treated chamber slides (LabTek/Thermo Scientific, Rochester, NY, USA), respectively. Cells were cultured in the conditions described above. Cells were fixed using 4% paraformaldehyde for 10 min and permeabilized with 0.1% Triton-X prior to staining with primary antibodies. 40 The following antibodies and dilutions were used: mouse nestin (Chemicon, Billerica, MA, USA) at 1:50, human nestin (Millipore, Billerica, MA, USA) at 1:200, glial fibrillary acidic protein (GFAP) (DAKO, Carpinteria, CA, USA) at 1:500, b-tubulin (Sigma, St Louis, MO, USA) at 1:400, and O 4 (Millipore) at 1:50. Images of slides were captured with a 100 Â objective using an Axiophot fluorescence microscope and analyzed using Axiovision 4.8 software (Zeiss, Thornwood, NY, USA).
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